Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 112 results for "sarabjit kour nangra"

Higher growth will bring the attrition rate down for Infosys: Sarabjit Kour Nangra
Business Standard

Higher growth will bring the attrition rate down for Infosys: ...

Interview with Sarabjit Kour Nangra, VP Research - IT, Angel Broking Faraan Tarique | Mumbai January 9, 2015 Last Updated at 16:00 IST Analysts are quite impressed by third-quarter results from Infosys as it turned out to be better than what they had ... Business Standard, 1 month ago

1 images for "sarabjit kour nangra"

Business Standard, 1 month ago

Sun Pharma surgs 6% amid sinking stock market

NEW DELHI: Sun Pharmaceuticals surged over 8 per cent in intraday trade to hit its 52-week high of Rs 1,006 after the drug maker said it would acquire the opiates business of British drug maker GlaxoSmithKline (GSK) in Australia, in a bid to capture ...
 Economic Times1 day ago Sun Pharma hits fresh 52-week high, up nearly 7% on plans to buy GSK unit  Economic Times1 day ago
Calcutta Telegraph

Sun Pharma buys GSK Aussie unit

Mumbai, March 3: Sun Pharmaceutical Industries today announced that it was acquiring the opiates business of GlaxoSmithKline (GSK) in Australia for an undisclosed amount. The acquisition is part of the Dilip Shanghvi-led company's plan to improve ...
 Calcutta Telegraph2 days ago Sun Pharma in pact to buy GSK's opiates business in Australia  Livemint.com2 days ago Sensex volatile, Midcap outperforms; Reliance, TCS rally  Moneycontrol.com2 days ago

Street undeterred by USFDA observations on Lupin's Indore plant

Lupin has been in the midst of news flow. While last week it announced developments on two respiratory products, on Monday it received final approval from USFDA to market generic version of Allergan Inc.'s Lumigan, an ophthalmic solution. The ...
 Business Standard India1 week ago Lupin's Pithampur unit under US FDA lens  DNA India1 week ago Lupin says FDA raises concerns over Pithampur plant  Livemint.com1 week ago
Calcutta Telegraph

Infy to buy Panaya for $200m

Mumbai, Feb. 16: Infosys will acquire US-based automation technology company Panaya for $200 million (over Rs 1,200 crore). The all-cash deal is the second-largest acquisition for the Bangalore-based firm, after Swiss consulting company ...
 Calcutta Telegraph2 weeks ago Infosys buys automation technology firm Panaya  The Financial Chronicle2 weeks ago Infosys buys US-based Panaya for $200 million  Oneindia2 weeks ago Infosys to buy automation tech firm Panaya for $200 mn  Business Standard India2 weeks ago
Calcutta Telegraph

Hard days for software exports

Mumbai,Feb. 10: IT-BPO exports are likely to grow at 12-14 per cent in the next fiscal, industry body Nasscom said today. The growth rate is lower than the 13-15 per cent guidance for this year. The slower growth projection has been attributed to ...
 Calcutta Telegraph3 weeks ago

Angel Broking recommends long term buy on Infosys, TCS and Wipro

According to Nasscom, revenues for IT sector are expected to grow at 13% in FY2015 to end the year, USD 146 billion. The revenue growth rate target stands at 13.1% in constant currency terms and 13.9% in rupee terms, the industry body said. The ...
 MyIris3 weeks ago
Business Standard India

Drugs of 7 Indian pharma cos in EMA's suspension list

Questions raised over integrity of clinical research data at a site operated by GVK Biosciences BS Reporter | Hyderabad February 3, 2015 Last Updated at 13:08 IST Several drugs manufactured and marketed by as many as seven Indian generic ...
 Business Standard India1 month ago Drugs of seven Indian pharma firms in EMA's suspension list  Smart Investor1 month ago Drugs of 7 Indian pharma firms in EMA's suspension list  Rediff.com4 weeks ago

Twin treat from TechM

Mumbai, Jan. 30: Tech Mahindra today announced a 1:1 bonus issue while splitting its stock in the ratio of 2:1 (two equity shares of Rs 5 each for every one equity share of Rs 10 each), offering a double bonanza to its investors. This is the ...
 Calcutta Telegraph1 month ago

Ranbaxy forfeits 180 days exclusivity for generic Nexium

NEW DELHI: Ranbaxy Laboratories has lost the opportunity to exclusively market in the United States for six months the first generic version of Anglo Swedish drug innovator Astra Zeneca's heartburn drug Nexium, the Delhi-based company said in a ...
 Times of India1 month ago Ranbaxy Laboratories : forfeits 180 days exclusivity for generic Nexium  4 Traders1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less